Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies.

(2010) P Conte et al.   CANCER RESEARCH

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

(2008) Francis Y. F. Lee et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I/II Study of Ixabepilone plus Capecitabine in Anthracycline–Pretreated/Resistant and Taxane-Resistant Metastatic Breast Cancer

(2008) Craig Bunnell et al.   Clinical Breast Cancer

Ixabepilone overcomes multiple mechanisms of drug resistance including overexpression of class III |i tubulin and breast cancer resistance protein

(2008) F. Lee et al.   EJC SUPPLEMENTS

Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment

(2008) Eva S. Thomas   JOURNAL OF CLINICAL ONCOLOGY

Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer

(2008) Martine J. Piccart-Gebhart et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessing the Measure of a New Drug: Is Survival the Only Thing That Matters?

(2008) Daniel J. Sargent et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Therapies for the Treatment of Breast Cancer in the Post-trastuzumab Era

(2008) F. Petrelli et al.   ONCOLOGIST